Immuneering Corp
IMRX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $282.7M
- Lead Asset:
- imm-1-104 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for IMRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMRX
Immuneering Corp (IMRX) is a clinical-stage biotechnology company developing Deep Cyclic Inhibition® product candidates targeting the MAPK pathway, with its lead asset atebimetinib (IMM-1-104) in a Phase 3 trial for pancreatic cancer and a second candidate envometinib (IMM-6-415) in Phase 1/2.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$282.7M
Cash Runway
—
Lead Asset
imm-1-104 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Immuneering Corp.
Immuneering Corp (IMRX) is a clinical-stage biotechnology company developing Deep Cyclic Inhibition® product candidates targeting the MAPK pathway, with its lead asset atebimetinib (IMM-1-104) in a Phase 3 trial for pancreatic cancer and a second candidate envometinib (IMM-6-415) in Phase 1/2.
- Lead candidate atebimetinib (IMM-1-104) is in a Phase 3 randomized study (MAPKeeper 301) for metastatic pancreatic ductal adenocarcinoma, with a topline data readout expected in mid-2028 [sec_mda · as of 2026-08-05].
- Reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel in a prior clinical update [news · published 2025-11-13].
- Cash & equivalents of $41.3M as of 2026-06-30, with shareholders' equity of $190.7M and a net loss of $17.3M for the period [latest reported financials].
- Accumulated deficit of approximately $311.1M as of June 30, 2026, with cash, cash equivalents and marketable securities of about $182.7M [sec_mda · as of 2026-08-05].
- Atebimetinib has received Fast Track and Orphan Drug designations from the FDA, and the company has clinical supply agreements with Regeneron and Eli Lilly for combination trials [pipeline].
What works
- Atebimetinib has shown promising early survival data (86% overall survival at 9 months) in first-line pancreatic cancer, supporting its Phase 3 advancement [news · published 2025-11-13].
- The company raised $225 million in financing, including a $25 million private placement with Sanofi, extending cash runway into 2029 [news · published 2025-11-13].
- Atebimetinib holds Fast Track and Orphan Drug regulatory designations, which may accelerate development and provide market exclusivity [pipeline].
- The company has a second clinical-stage candidate, envometinib (IMM-6-415), targeting RAS/RAF mutated solid tumors, diversifying its pipeline [pipeline].
What to weigh
- Immuneering has no internally developed products approved for sale and does not expect product revenue until at least one candidate is successfully developed and approved [sec_mda · as of 2026-08-05].
- The company reported a net loss of $17.3M for the period ending 2026-06-30 and an accumulated deficit of $311.1M, indicating ongoing negative cash flow [latest reported financials; sec_mda · as of 2026-08-05].
- The Phase 3 MAPKeeper 301 trial for atebimetinib is not expected to read out until mid-2028, leaving a long period without a potential value-inflection catalyst [sec_mda · as of 2026-08-05].
- Envometinib (IMM-6-415) is in early Phase 1/2 and faces a competitive landscape with over 160 other programs targeting similar indications [pipeline].
From the filings
Quoted directly from source documents.
Atebimetinib is in a Phase 3 trial for pancreatic cancer with a topline readout expected in mid-2028.
“in mid-2028, providing a topline data readout from the MAPKeeper 301 trial”
SEC MD&A · August 5, 2026
86% overall survival at 9 months was reported in first-line pancreatic cancer patients treated with atebimetinib + mGnP.
“Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP”
News · November 13, 2025
The company has an accumulated deficit of $311.1M as of June 30, 2026.
“we had an accumulated deficit of approximately $311.1 million”
SEC MD&A · August 5, 2026
Catalyst timeline
- 2026-06-05 · Phase 3 start of MAPKeeper 301 (atebimetinib + mGnP vs GnP in pancreatic cancer) — Initiation of the pivotal Phase 3 trial; topline readout expected mid-2028.
Risks & what to watch (4)›
Key risks
- No approved products — No internally developed products approved for sale; no product revenue expected until at least one candidate is approved [sec_mda · as of 2026-08-05].
- Long path to Phase 3 readout — Topline data from MAPKeeper 301 not expected until mid-2028, leaving a multi-year gap without a major catalyst [sec_mda · as of 2026-08-05].
- Accumulated deficit — Accumulated deficit of $311.1M as of June 30, 2026, reflecting sustained R&D spending without product revenue [sec_mda · as of 2026-08-05].
- Competitive pipeline — Envometinib faces over 160 competitors in RAS/RAF-mutated solid tumors, increasing development risk [pipeline].
What to watch
- Preliminary data readout from atebimetinib + Libtayo combination trial in non-small cell lung cancer expected late-2027 [sec · filed 2026-06-01].
- Additional pre-clinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer expected in Q4 2026 [sec · filed 2026-06-01].
- IND-enabling studies for the next Deep Cyclic Inhibition® product candidate program expected to begin in mid-2027 [sec_mda · as of 2026-08-05].
- Topline data readout from the Phase 3 MAPKeeper 301 trial for atebimetinib in pancreatic cancer expected in mid-2028 [sec_mda · as of 2026-08-05].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Immuneering Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immuneering Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 19.4%
- Days to cover
- 12.4
- Shares short
- 9,500,184
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immuneering Corp?
Immuneering Corp (IMRX) is a clinical-stage biotechnology company developing Deep Cyclic Inhibition® product candidates targeting the MAPK pathway, with its lead asset atebimetinib (IMM-1-104) in a Phase 3 trial for pancreatic cancer and a second candidate envometinib (IMM-6-415) in Phase 1/2.
What is Immuneering Corp's lead drug candidate?
Immuneering Corp's most advanced tracked candidate is imm-1-104 (Phase 2) for Advanced Solid Tumor.
Who is the CEO of Immuneering Corp?
Dr. Benjamin J. Zeskind M.B.A., Ph.D. is the chief executive officer of Immuneering Corp (IMRX).
Where is Immuneering Corp headquartered?
Immuneering Corp (IMRX) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Immuneering Corp focus on?
Immuneering Corp develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.